What is the medical insurance policy for Selumetinib in 2025?

Selumetinib (Selumetinib) is a new MEK inhibitor that provides a new option for targeted therapy for pediatric patients with symptomatic, unresectable plexiform neurofibromatosis (PN) associated with neurofibromatosis type I (NF1). In 2025, the original drug selumetinib has been officially launched in China and has been included in the national medical insurance directory, providing financial support to eligible patients.

The introduction of medical insurance reimbursement means that families can reduce the burden of medicines, especially the high cost of medicines required for long-term treatment. Common domestic specifications include10mg 60 capsules and 25mg 60 capsules, with each box selling for more than 20,000 yuan. Since this drug is mainly used for children aged 3 years and above, clinical use needs to be carried out under the guidance of a specialist.

Selumetinib interferes with the growth of plexiform neurofibromas by inhibiting theMEK1/2 signaling pathway. Plexiform neurofibromas in patients with NF1 tend to increase in size with age and may cause pain, functional disability, or cosmetic distress. Traditional surgical resection has problems such as high recurrence rate and heavy trauma. Selumetinib, as an oral targeted drug, can play unique advantages in reducing tumor burden and improving quality of life. Medical insurance policy coverage makes long-term treatment possible, and patients and families can continue to receive drug support, reducing financial pressure while ensuring continuity and compliance of treatment.

In actual use, the medical insurance reimbursement ratio and reimbursement process may vary from region to region. When purchasing, patients need to bring valid medical records, doctor's prescriptions and medical insurance cards to the designated pharmacy or hospital to apply. Some regions may also require hospitals to provide diagnosis certificates and tumor imaging data to prove that the indications comply with medical insurance regulations. With the support of medical insurance policies, the utilization rate of selumetinib among children with NF1 is expected to further increase, providing standardized and sustainable treatment options for more children.

Reference materials:https://www.koselugo.com